Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
Text Size

hCAP18 Levels and Vitamin D Deficiency in Healthy Subjects

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Ishir Bhan, MD, MPH, Massachusetts General Hospital
ClinicalTrials.gov Identifier:
NCT00742235
First received: August 25, 2008
Last updated: September 9, 2013
Last verified: September 2013
History of Changes

August 25, 2008
September 9, 2013
July 2007
January 2012   (final data collection date for primary outcome measure)
  • hCAP18 Levels [ Time Frame: Baseline ] [ Designated as safety issue: No ]
  • Baseline 25-OH Vitamin D Level [ Time Frame: Baseline ] [ Designated as safety issue: No ]
hCAP18 levels [ Time Frame: 2 weeks ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00742235 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
hCAP18 Levels and Vitamin D Deficiency in Healthy Subjects
hCAP18 Levels and Vitamin D Deficiency in Healthy Subjects

Vitamin D deficiency (low levels of vitamin D in the blood) is a common problem. A recently discovered protein, called hCAP18, likely plays an important role in the immune system and may depend on adequate levels of vitamin D. It is not known what levels of vitamin D are needed to allow the body to make this protein. Nor is it known if giving vitamin D to people who are found to be deficient will help boost levels of hCAP18. This study aims to clarify the relationship between vitamin D levels and hCAP18.
Not Provided
Interventional
Not Provided
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Healthy Subjects
  • Vitamin D Deficiency
Drug: ergocalciferol
Ergocalciferol 50,000 IU given every other day for 5 total doses
Other Name: Vitamin D
  • Experimental: 1
    Vitamin D insufficient (treated with ergocalciferol 50,000 IU every other day x 5 doses)
    Intervention: Drug: ergocalciferol
  • No Intervention: Vitamin D sufficient
    Subjects who did not receive ergocalciferol and had a 25-OH vitamin D level >32 ng/ml
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
99
January 2012
January 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Age 18-80

Exclusion Criteria:

  • Known active infectious disease or chronic inflammatory disorder
  • Hypercalcemia
  • Chronic kidney disease
  • Pregnancy
Both
18 Years to 80 Years
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00742235
2008-P-0003000/1
No
Ishir Bhan, MD, MPH, Massachusetts General Hospital
Massachusetts General Hospital
Not Provided
Principal Investigator: Ishir Bhan, MD MPH Massachusetts General Hospital
Massachusetts General Hospital
September 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP